These 3 marijuana stocks turned $10,000 into $206,000

Find out what’s lifted these big players so far so quickly.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This article was originally published on Fool.com

It’s easy to forget during turbulent markets that over the long haul, stocks have helped long-term investors create life-changing wealth. Even just using index funds, disciplined investors who’ve put money to work regularly in the stock market have seen their savings climb dramatically. Those who’ve identified promising niches of the market have done far better.

Marijuana stocks have gotten a lot of attention lately because of the trend toward greater acceptance and legalization of cannabis products. That reached a peak when Canada legalized recreational marijuana earlier this month, but even after a healthy pullback in cannabis stocks, longtime investors in the space have seen impressive gains. If you’d invested $10,000 in equal parts in marijuana stocks Canopy Growth (NYSE:CGC)Cronos Group (NASDAQ:CRON), and Aurora Cannabis (NYSE:ACB) on various Canadian stock exchanges three years ago, you’d be sitting on a portfolio worth more than $200,000 today. The big question now is whether these three key cannabis leaders can keep up the positive momentum.

WEED Chart

WEED DATA BY YCHARTS.

The best-known pot stock

Canopy Growth has the strongest reputation among marijuana investors, largely because it’s gotten the most attention from the mainstream corporate world outside of the cannabis industry. Canopy has attracted two separate investments from beer giant Constellation Brands, including a nearly $4 billion investment just a few months ago. The deal has helped raise awareness of the entire sector, and other marijuana companies have sought partnerships of their own in order to give them the cachet that Canopy Growth has.

Canopy has become a leader in the industry because of its immense production capacity, which puts it squarely at the top of the business currently. Yet Canopy isn’t content to rest on its laurels, and it’s working hard to expand production further. At the same time, the cannabis company’s early success in creating its Tweed brand of cannabis products demonstrates its business savvy. Even with its stock having jumped almost 1,800% in the past three years, Canopy Growth has more room to run higher.

Several packages of cannabis products on a wooden shelf in front of a wood-paneled wall.

IMAGE SOURCE: CANOPY GROWTH.

Leader of the pack

Cronos Group has the distinction of being the best-performing marijuana stock of all time right now. Despite having seen a pullback over the past few weeks, Cronos has posted gains of more than 2,700% over the past few years. Having formerly been known as PharmaCan Capital, Cronos has been a big player in the medical marijuana segment of the cannabis industry.

Like Canopy, Cronos has worked hard to boost its production capacity. Another avenue for growth involves international distribution, with partnerships giving it access to markets in Australia, Israel, Germany, Poland, and various points in Latin America. With a new collaboration with Ginkgo Bioworks to develop cannabis derivatives of high purity, Cronos hopes it can tap into growing markets for both medicinal and recreational use. If it’s successful, that could lead to even bigger gains for Cronos.

Aurora hits the NYSE

Finally, Aurora Cannabis is best known for its recent listing on the New York Stock Exchange. Yet even before that, the stock managed to produce gains of 1,400% on exchanges in Canada.

Aurora has focused its efforts on building up production capacity as quickly as possible, trying to keep up with and surpass Canopy Growth with projects including its Aurora Sun facility near the Edmonton International Airport and similar growth facilities in eastern Alberta and in Denmark. With investments in other players in the cannabis industry, Aurora is also trying to stay diversified and build key collaborations that it can use to grow more efficiently. That’ll be essential as it strives to maintain its competitive position in the rapidly evolving marijuana market.

Further gains to come?

Marijuana stocks have produced amazing gains, and now that they’re squarely on the radar of mainstream investors, it’ll be hard to see 20-fold increases from current levels. Nevertheless, for those who see the potential profits from cannabis, Aurora Cannabis, Cronos Group, and Canopy Growth all deserve future attention to see how they can build on their early success.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool US recommends Constellation Brands. The Motley Fool has a disclosure policy.

More on Investing Articles

Investing Articles

With an 8% yield and a P/E below 12, Taylor Wimpey looks in deep value territory

Harvey Jones wants to make a bit of noise about Taylor Wimpey shares. The FTSE 100 stock may be volatile…

Read more »

A young Asian woman holding up her index finger
Investing Articles

Up 8% today, is this one of the FTSE 100 best growth shares to buy?

Looking for the best FTSE 100 growth shares for a winning portfolio? This soaring blue chip is worth serious consideration,…

Read more »

Investing Articles

With yields over 7%, here are two FTSE 100 dividend shares to consider in 2025

As the FTSE 100 trades near all-time highs in 2025, some of its top dividend shares still offer highly attractive…

Read more »

Investing Articles

Here’s why Coca-Cola HBC stock jumped over 9% in the FTSE 100 today

This stock was flying to a record high in the FTSE 100 today, boosted by a strong set of earnings.…

Read more »

Investing Articles

1 FTSE 100 stock an investor consider for a Stocks and Shares ISA if Cash ISAs get canned

The talk in the papers is of the Cash ISA getting axed, but the Stocks and Shares ISA seems secure.…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

A 5.5% dividend forecast? £2k invested in Lloyds shares could earn an investor this much by 2027

Jon Smith talks through the dividend forecast for Lloyds stock in the coming years and weighs up whether it could…

Read more »

Investing Articles

How much in savings would investors need to target a £3,000 monthly passive income?

Our writer outlines a simple recipe to earn passive income from shares. The ingredients include diligent saving, ample time and…

Read more »

Investing Articles

The average Stocks and Shares ISA turned £10k into £25k in a decade. I aim to beat that

Harvey Jones is impressed by the long-term total return on the average Stocks and Shares ISA. Yet he still reckons…

Read more »